Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
<p>Disease-free survival and overall survival in patients who extended therapy and those who did not. <b>A</b> and <b>B,</b> Disease-free survival (<b>A</b>) and overall survival (<b>B</b>). Note: HR was adjusted for age at diagnosis, calendar pe...
Sparad:
| Huvudupphovsman: | |
|---|---|
| Övriga upphovsmän: | , , , |
| Publicerad: |
2025
|
| Ämnen: | |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
| _version_ | 1849927639750410240 |
|---|---|
| author | Erwei Zeng (14958443) |
| author2 | Wei He (14958446) Arvid Sjölander (14958449) Jenny Bergqvist (14958452) Kamila Czene (14958455) |
| author2_role | author author author author |
| author_facet | Erwei Zeng (14958443) Wei He (14958446) Arvid Sjölander (14958449) Jenny Bergqvist (14958452) Kamila Czene (14958455) |
| author_role | author |
| dc.creator.none.fl_str_mv | Erwei Zeng (14958443) Wei He (14958446) Arvid Sjölander (14958449) Jenny Bergqvist (14958452) Kamila Czene (14958455) |
| dc.date.none.fl_str_mv | 2025-11-24T22:42:28Z |
| dc.identifier.none.fl_str_mv | 10.1158/0008-5472.30699293 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_4_from_Determinants_and_Effectiveness_of_Extending_the_Duration_of_Adjuvant_Hormone_Therapy_beyond_5_Years_in_Patients_with_Breast_Cancer/30699293 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Cancer Care and Survivorship Epidemiology Breast Cancer Epidemiology Survivorship Research Epidemiology of survivorship |
| dc.title.none.fl_str_mv | Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Disease-free survival and overall survival in patients who extended therapy and those who did not. <b>A</b> and <b>B,</b> Disease-free survival (<b>A</b>) and overall survival (<b>B</b>). Note: HR was adjusted for age at diagnosis, calendar period of cancer diagnosis, tumor size, lymph node status, tumor grade, progesterone receptor status, chemotherapy, radiotherapy, Charlson Comorbidity Index at extension, education, and income at diagnosis.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_a60633b6ed1423574254a1d200d2d863 |
| identifier_str_mv | 10.1158/0008-5472.30699293 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30699293 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast CancerErwei Zeng (14958443)Wei He (14958446)Arvid Sjölander (14958449)Jenny Bergqvist (14958452)Kamila Czene (14958455)CancerCancer Care and SurvivorshipEpidemiologyBreast CancerEpidemiologySurvivorship ResearchEpidemiology of survivorship<p>Disease-free survival and overall survival in patients who extended therapy and those who did not. <b>A</b> and <b>B,</b> Disease-free survival (<b>A</b>) and overall survival (<b>B</b>). Note: HR was adjusted for age at diagnosis, calendar period of cancer diagnosis, tumor size, lymph node status, tumor grade, progesterone receptor status, chemotherapy, radiotherapy, Charlson Comorbidity Index at extension, education, and income at diagnosis.</p>2025-11-24T22:42:28ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/0008-5472.30699293https://figshare.com/articles/figure/Figure_4_from_Determinants_and_Effectiveness_of_Extending_the_Duration_of_Adjuvant_Hormone_Therapy_beyond_5_Years_in_Patients_with_Breast_Cancer/30699293CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/306992932025-11-24T22:42:28Z |
| spellingShingle | Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer Erwei Zeng (14958443) Cancer Cancer Care and Survivorship Epidemiology Breast Cancer Epidemiology Survivorship Research Epidemiology of survivorship |
| status_str | publishedVersion |
| title | Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| title_full | Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| title_fullStr | Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| title_full_unstemmed | Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| title_short | Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| title_sort | Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer |
| topic | Cancer Cancer Care and Survivorship Epidemiology Breast Cancer Epidemiology Survivorship Research Epidemiology of survivorship |